Barely Significant
← all excerpts

KRAS is a prognostic biomarker associated with diagnosis and treatment in multiple cancers.

Front Genet · 2022 · PMC9624065 · PMID 36330448

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

extremely significantno p-value reported
A total of 12 kinds of tumor tissues has significant difference in KRAS expression levels, of which 9 tumor tissues BRCA (Breast invasive carcinoma), CHOL (Cholangiocarcinoma), COAD (Colon adenocarcinoma), KIRC (Kidney renal clear cell carcinoma), LUAD (Lung adenocarcinoma), LUSC (Lung squamous cell carcinoma), READ (Rectum adenocarcinoma), STAD (Stomach adenocarcinoma), and UCEC (Uterine Corpus Endometrial Carcinoma) had an extremely significant difference; meanwhile, 3 tumor tissues (GBM (Glioblastoma multiforme), LIHC(Liver hepatocellular carcinoma), and THCA(Thyroid carcinoma) had a significant difference ( Figure 1 ).

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.